Company intelligence / Profile preview

Mabwell

Shanghai, Shanghai, Chinamabwell.com ↗

Ownership: Public · 688062
Development stage: Phase 3

Overview

Mabwell has multiple products in various clinical stages, including approved biosimilars, Phase 3 candidates, and early-stage pipeline assets. The company recently presented clinical data on 9MW2821 combined with Toripalimab in UC patients and received NMPA approval to initiate clinical trials for a novel B7-H3-targeting ADC for advanced solid tumors.

Therapeutic areas: GastroenterologyPulmonologyRheumatologyOphthalmologyImmunologyEndocrinologyHematologyOncology
Modalities: Monoclonal antibodiesAntibody drug conjugates (ADC)Fusion proteinsBiosimilarsRecombinant proteins
Industry: Biotech

Drug pipeline

36 assets

9MW0813

Approved

35 more assets in the full pipeline.

Request access →

Partnerships

Insilico MedicineDP TechnologyJunshi BiosciencesJiangsu T-Mab Biopharma Co.,Ltd

Beyond the preview

Go deeper on Mabwell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mabwell.

Explore the full profile